source
- Immunovant halts cutaneous lupus program after phase 2 failureImmunovant announced it is discontinuing development of its anti-FcRn antibody IMVT-1402 for cutaneous lupus erythematosus. The decision follows a mid-phase trial that did not meet its primary end…
- Trump's Department of War bets $47M on Flagship biotechs to develop countermeasuresThe Department of War has awarded Flagship Pioneering $47 million to develop medical countermeasure technologies against emerging threats.